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Abstract
Excretion of urinary N-acetyl -D-glucosaminidase
(NAG) and its isoenzyme patterns were studied in
two groups of patients with rheumatoid arthritis
(RA) and in normal control subjects. Urine samples
were collected from 30 seropositive RA patients, 19
seronegative RA patients, and 15 normal healthy
subjects. All the patients and normal subjects were
assessed to have normal liver and kidney functions.
A small portion of the urine sample was dialyzed
against 0.01 M phosphate buffer, pH 7.0 and NAG
activity was monitored. Mean ± SD values of urinary
NAG in seropositive RA patients, in seronegative
RA patients and in normal healthy subjects were
found to be 4.20 ± 3.73 U/g creatinine, 2.96 ± 2.11
U/gm creatinine, and 1.71 ± 0.6 U/g creatinine,
respectively. The mean urinary NAG value in RA
patients was found to be significantly higher (P <
0.05) in seropositive RA compared to the mean NAG
value in normal healthy subjects and patients with
seronegative RA when analyzed by one way ANOVA
and Tukey-HSD test. The mean proportion of isoenzyme form B to isoenzyme form A in seropositive
RA patients was also found to be significantly
different (P < 0.05) from the mean proportion of these
forms in normal healthy subjects and seronegative RA
patients. There also appears to be a correlation
between the concentration of urinary NAG and
severity of the disease in seropositive RA.
Key Words: N-acetyl-β-D-glucosaminidase, rheumatoid
arthritis, seropositive, seronegative, isoenzymes

Introduction
N-Acetyl β-D -glucosominidase (NAG) is a lysosomal
enzyme, which is mainly present in proximal convoluted
tubules. Its levels in urine have been shown to be elevated
in a number of diseases, such as diabetes mellitus (Whiting
et al., 1979a; 1979b; Hanseus et al., 1983; Shimajo et
al., 1987; Skrha et al., 1987; Severni et al., 1988; Watts
et al., 1988), renal stone disease (Javed et al., 1992) and
impaired renal function disorders (Ellis et al., 1975). More
recently, it has been reported that urinary NAG levels are
elevated in adjuvant arthritis (Franch et al., 1990) and
there appears to be a positive correlation between urinary
NAG excretion and severity of the disease. The present
study was undertaken to investigate the excretion of
urinary NAG and the pattern of its isoenzymes in different
types of rheumatoid arthritis (RA) and compare these
values with those in normal healthy subjects. Another
objective was to see if there was any correlation between
urinary levels of NAG and severity of the disease.

Materials and Methods
Forty-nine adult patients (mean age 44 years) who were
diagnosed to have RA as defined by the criteria of the
American Rheumatism Association were included in this
study. Out of these, 30 (24 females and 6 males) were
found to have seropositive RA, while 19 (15 females
and 4 males) were having seronegative RA. Moreover,
15 normal healthy subjects in the same age group were
taken as “controls”.
Severity of the RA was assessed to be mild, moderate
or severe depending upon the number of swollen joints
and deformities. Those having involvement of 1-2 joints
and no deformities were placed in the mild disease subgroup, while those with involvement of 3-10 joints and
deformities of either hands or feet were placed in the
moderate disease subgroup. When there were more than
10 swollen joints and deformities of both hands and feet,
these patients were placed in the severe disease subgroup.
Mean duration of RA in each subgroup was also taken
into account. All the RA patients were also assessed to
have normal kidney and liver functions. Those patients
who had received gold as antirheumatic treatment were
not included in this study.

Analysis of NAG
Morning urine samples were collected from the two groups
of arthritis patients as well as from normal healthy subjects.
These were dialyzed against 10 mM phosphate buffer,
pH 7.0 for 4 h. NAG activity in the dialyzed samples was
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determined by the method of Whiting et al. (1979b). This
procedure involves incubation of 0.1 ml of urine diluted
with 0.4 ml of distilled water and 4.5 ml of 20 mM citratephosphate buffer, pH 4.4 containing 0.2 mM methylumbelliferyl-glucosaminidine at 37˚C. One ml from this
is then withdrawn at various time intervals (0 min, 5 min,
10 min, 15 min) and transferred to separate tubes
containing 2 ml of 0.5 M glycine-NaOH buffer, pH 10.4,
to stop the reaction.
The fluorescence of 4-methyl umbelliferone (MU)
released in each reaction was monitored spectrofluorimetrically at excitation and emission wavelengths of
368 and 448 nm, respectively using JASCO FP-770
s p e c t r o - f l u o r i m e t e r. One unit of NAG activity was
defined as that which released 1 mmole of 4 MU per
minute under assay conditions. In order to compensate
for the production of concentrated or diluted urine
samples, NAG activities in urine were expressed as U
per gm of urinary creatinine. Urinary creatinine was
measured by Boehringer Mann-heim Diagnostics Kit
based on Jaffe’ method.

Separation of NAG isoenzymes
Separation of NAG isoenzymes in urine samples was
carried out by using a modification of the procedure
described by Severni et al. (1988). One ml of dialyzed
urine sample was applied to a minicolumn of DEAESepharose (1.5 cmለ3.0 cm) which had been equilibrated
with 50 mM phosphate buffer, pH 7.2. The flow rate of
the column was adjusted to 15 ml/h. One-ml fractions
were collected. First 10 fractions, which contained NAGB isoenzyme, were collected with 50 mM phosphate
buffer, pH 7.2, while NAG-A isoenzyme was eluted using
1 M NaCl. NAG activity in the fractions was determined
spectrofluorimetrically as described above.

Statistical analysis
To compare the distribution of mean values of urinary
NAG among various groups under study, one way
ANOVA and Tukey-HSD test were used. Comparison of
the mean values of two subgroups was also carried out
by student- t test.

Results
Figure 1 shows the mean ± SD urinary NAG values in
the seropositive RA group, seronegative RA group and
normal control group. The mean NAG values in these
three groups were compared by using one way ANOVA
followed by Tukey-HSD test. One way ANOVA indicated
that the mean NAG values were significantly different
(P-value = 0.027, F statistics = 3.8377). Tukey-HSD test
at 5% significance level further revealed that the mean
NAG value in the seropositive RA group was
significantly d i fferent from the mean NAG values in
normal control group and seronegative RA group.
Since one of the objectives of this study was to see if
there was any correlation between urinary NAG activity
and severity of the disease, RA patients in this study
were classified into mild, moderate and severe disease
subgroups as described in the Materials and Methods
section. Urinary NAG values in these three subgroups
have been reported in Tables 1 and 2.
Comparison of the distribution of NAG values in these
subgroups revealed an apparent correlation between
mean value of NAG and severity of the disease in seropositive group of RA patients. This was due to the fact that
a comparison of the mean NAG values between severe
and mild disease subgroups by student-t test yielded a

Figure 1. Urinary NAG activity in two groups of
rheumatoid arthritis compared to normal control
group (n = number of subjects; SD = Standard
Deviation). Comparison of the distribution of urinary
NAG values in these 3 groups was carried out by
using one way ANOVA and Tukey-HSD test.

Urinary NAG in rheumatoid arthritis

Table 1. Comparison of the distribution of urinary NAG values in mild, moderate and
severe disease subgroups of seropositive RA. One way ANOVA P-value = 0.21.
Comparison of the mean NAG values between severe and mild disease subgroups by
student-t test, however, reveals a significant difference at P < 0.05.

Disease

Sample

Mean duration

Sample Mean

Condition

size (n)

of RA ± SD

NAG value ± SD

(years)

(U/g creatinine)

Mild

6

4.67 ± 0.47

2.33 ± 1.20

Moderate

12

4.87 ± 3.9

3.82 ± 3.73

Severe

12

7.12 ± 3.45

5.52 ± 4.25

Table 2. Comparison of the distribution of urinary NAG values in mild, moderate and
severe disease subgroups of seronegative RA. One way ANOVA P-value = 0.803.

Disease

Sample

Mean duration

Sample Mean

Condition

size (n)

of RA ± SD

NAG value ± SD

(years)

(U/g creatinine)
3.16 ± 2.2

Mild

13

1.7 ± 1.47

Moderate

1

0.33

3.25

Severe

5

5.89 ± 7.03

2.57 ± 2.36

significant difference at P < 0.05 (Table 1). However,
when we compared the mean values using more stringent
statistical tests, such as one way ANOVA and TukeyHSD test, no significant difference was observed
between the mean NAG values in mild, moderate and
severe subgroups of seropositive as well as
seronegative groups of RA patients (Tables 1 and 2).
Figure 2 shows a typical chromatogram of NAG isoenzymes in the urine samples of a seropositive RA patient,
a seronegative RA patient, and a normal healthy subject
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Table 3. Comparison of the mean values of the ratio of isoenzyme B to isoenzyme A in
two groups of rheumatoid arthritis and a normal control group. One way ANOVA Pvalue = 0.017. Comparison of the mean values was carried out by using one way
ANOVA and Tukey-HSD test.
Group

Sample size (n)

Mean ± SD
isoenzyme B/isoenzyme A

Normal

7

0.407 ± 0.22

Seronegative RA

9

0.795 ± 0.38

Seropositive RA

15

1.284 ± 0.85

eluted from a DEAE-Sepharose column. All the three
samples resolved into NAG-B and NAG-A isoenzymes.
The mean values of the proportion of NAG-B to NAG-A
in the urine samples of three groups of subjects in this
study have been shown in Table 3. One way ANOVA
showed the mean proportion values of NAG-B/NAG-A
to be significantly different among three groups (P-value
= 0.017, F statistics = 4.74). Tukey-HSD test further
indicated that the mean value of NAG-B / NAG-A obtained
in seropositive RA patients was statistically different from
the mean values obtained in normal healthy subjects and
in seronegative RA patients at 5% significance level. This
suggests that the increase in total urinary NAG, at least
in seropositive RA patients, is contributed mainly by NAGB isoenzyme.

Discussion
This study shows that total activity of NAG in urine is
significantly elevated in seropositive RA patients compared
to normal healthy subjects. Urinary NAG is known to be
a sensitive indicator of kidney injury as its levels
increase before other renal function tests (especially

Figure 2. A typical chromatogram of NAG
isoenzymes (NAG-A and NAG-B) in urine of
a normal healthy subject and two patients
suffering rheumatoid arthritis after elution
from a DEAE-Sepharose column.
Experimental conditions have been
provided in the ‘Materials and Methods’
section.
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serum crea-tinine) become abnormal (Price, 1982).
Therefore, increased excretion of NAG may reflect renal
damage in RA. This is further supported by the
observation that the apparent value of urinary NAG in
most cases of severe seropositive RA appeared to be on
the higher side compared to the mild cases of this
disease. A similar correlation has pre-viously been
reported between urinary NAG and degree o f
nephropathy in diabetic patients (Whiting et al ., 1979a;
Shimajo et al., 1987; Skrha et al., 1987; Jung et al., 1988;
Watts et al., 1988), however, no clear correlation to
degree of retinopathy was established in these patients
with complications of diabetes mellitus (Agardh et al.,
1987, 1991; Watts et al., 1988). This shows that any
disease having a direct or indirect effect on kidney
tubular function would be expected to be associated with
increased levels of NAG in the urine. Franch et al.,
(1990) have also reported a positive association
between urinary NAG excretion and disease severity in
adjuvant arthritis.
In an earlier communication we have reported increased
levels of serum NAG in different arthopathies including
RA (Iqbal et al., 1998). However, it is unlikely that the
increased level of NAG in urine is contributed by the
increased level of this enzyme in serum as the molecular
size of the enzyme is high enough to prevent its
passage through the glomerulus. Thus, the origin of
urinary NAG appears to be the kidney tubules. Since we
measured the values of NAG as units/gm of creatinine,
any change occurring in the clearance of creatinine as a
result of concomitant use of drugs affecting glomerular
filtration rate, such as, non-steroidal anti-inflammatory
drugs (NSAIDs) etc. are not likely to interfere with our
results.
Isoenzymes of NAG (NAG-B and NAG-A) in urine have
been reported to be of value in assessing complications
of diabetes mellitus (Severini et al., 1988; Agardh et al.,
1991). It has been shown that only low amounts of NAGB are present in normal urine, however, the activity of
this isoenzyme significantly increases in most cases of
diabetes mellitus (Severini et al., 1988). Our results also
show that the ratio of NAG-B to NAG-A significantly
increases in severe cases of seropositive RA.
Renal damage is not uncommon in RA, but the causative
role of the disease per se has not been defined as yet
(Manganaro et al., 1994). Yoshida et al. (1991) have
reported two cases of native nephropathy in RA. Our
data also suggest that subclinical renal injury without
compromising renal function is a possibility in RA especially in severe cases of this disease. It is unclear which
factors lead to increased excretion of NAG (especially the
isoenzyme form B) in RA patients. The role of (NSAIDs)
and certain disease modifying antirheumatic drugs, such
as, gold in producing nephropathy cannot be discounted
(Yoshida et at., 1991. Kordonouri et al., 1994). Keeping
that in view, we have not included in this study those

patients who had received gold therapy. According to
the study by Kordonouri et al., (1994) subclinical renal
injury due to therapeutic doses of NSAIDs is more likely
to affect the glomerular function rather than the tubular
function. Hence, NAG, which is an enzyme marker for
the tubular function, is not expected to increase in urine
due to therapeutic doses of NSAIDs. In a more recent
study, Wiland et al. (1997) have reported NAG to be a
more sensitive indicator of kidney dysfunction in RA than
microalbuminuria. They also showed that methotrexate
in low dosages does not cause any marked damage to
renal proximal tubules.
All these reports lend further support to the notion that
subclinical damage to kidney may occur in RA. Determination of serum creatinine which is a routine procedure
for assessing kidney function is unlikely to detect those
changes as increased concentration of creatinine in serum
is not observed until over half of the glomerular function
is compromised (Lente and Suite, 1989). Determination
of urinary NAG along with excretion of creatinine may,
therefore, serve as a more sensitive test for kidney injury
in RA and measurement of the levels of its isoenzymes
could be of value in providing additional diagnostic
information regarding the status of this disease.
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